Joerg Herrmann MDProfessor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently he is an Associate Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and is the editor of the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib.
Recent Contributions to PracticeUpdate:
- Drug-Eluting Stents Superior to Bare-Metal Stents in Saphenous Vein Bypass Graft Post-CABG
- Prognostic Value of Fractional Flow Reserve Linking Physiologic Severity to Clinical Outcomes
- Predictive Models of Heart Failure Among Childhood Cancer Survivors
- Restenosis After Coronary Stenting Predicts 4-Year Mortality
- Coronary Liposuction During PCI Reduces Culprit Lesion Lipid Content Prior to Stent Placement
- The 2014 Guidelines for Managing Non–ST-Elevation Acute Coronary Syndromes
- Coronary Artery Bypass Grafting May Improve Quality of Life
- Additional Key Studies From TCT 2014: ABSORB II and PRIMA
- New Study Compares Cost-Effectiveness of Transcatheter Aortic Valve Replacement With Surgical Valve Replacement in High Risk Patients
- Five-Year Data From Clinical Trial Studying Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Demonstrates Persistent Mortality Benefit and Lower Rate of Repeat Hospitalizations Compared to Standard Therapy